POLITICS

Senate Republicans Block Sanders Amendment to Cut US Drug Prices by More Than 50%

April 24th, 2026

Senate Republicans voted in the early hours of Thursday morning to reject an amendment offered by Sen. Bernie Sanders that aimed to cut US prescription drug prices in half by mandating that Americans pay no more for medications than people in Canada and other wealthy nations.

Just two Republicans, Sens. Josh Hawley of Missouri and Dan Sullivan of Alaska, voted with every present Democrat in support of Sanders’ (I-Vt.) proposed amendment to the GOP’s emerging budget reconciliation package. Republicans plan to use the legislative vehicle to fund the Department of Homeland Security and its component agencies, principally Immigration and Customs Enforcement (ICE) and Customs and Border Protection (CBP).

The amendment vote put nearly every Senate Republican on the record against a policy supported by President Donald Trump. Last year, Trump signed an executive order directing federal health officials to “communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices for American patients in line with comparably developed nations.”

FitAid - Performance Products for Passionate People


But experts have noted that, without congressional action giving the federal government more power over drug pricing, pharmaceutical companies would not be required to comply with the proposed targets—rendering Trump’s order effectively meaningless. Drug prices have continued to rise in the US despite Trump’s order and his outlandish, mathematically impossible claims.

“If Trump is serious about making real change rather than just issuing a press release,” Sanders said last year in response to Trump’s executive order, “he will support legislation I will soon be introducing to make sure we pay no more for prescription drugs than people in other major countries. If Republicans and Democrats come together on this legislation, we can get it passed in a few weeks.”

The Sanders-led amendment that Republicans blocked on Thursday called for reducing “the price of prescription drugs in the United States by more than 50% by adopting most-favored-nation drug pricing so that the American people pay no more for prescription drugs than Europeans or Canadians.”

Ravin Crossbow - R10X XK7

Research has shown that Americans pay at least twice as much on average for prescription drugs as people in other wealthy nations.

“This amendment is very simple,” Sanders said during Senate debate on Thursday. “It would prevent pharmaceutical companies from charging more for prescription drugs in the United States than they do in Canada, the UK, Germany, France, and Japan.”

Last May, Sanders and several of his Democratic colleagues in the Senate introduced the Prescription Drug Price Relief Act, which would require federal health officials to “review brand-name drugs annually for excessive pricing and, if a drug is found to be priced excessively, to void any exclusivity granted to its sponsor.”

“Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan,” according to a summary of the legislation. “If a price does not meet this criteria, or if pricing information is unavailable in at least three of these countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population.”

Curated By

Elena Moretti
Field Medic/Combat Medic | Investigative Journalist/Social Affairs Correspondent | Human Rights Researcher/Advocacy Coordinator
Elena Moretti, a former field medic turned journalist who brings a uniquely humanitarian lens to global storytelling. With her background in emergency medicine, Elena understands firsthand the fragility of human life and the paramount importance of compassion in crisis. Her work consistently illuminates the personal stories behind headlines, giving voice to refugees fleeing conflict, examining how medical innovations reach those who need them most, and ensuring that progress doesn't leave vulnerable populations behind. As the moral compass of our editorial team, Elena anchors each piece in fundamental questions: Who suffers? Who benefits? And how can journalism serve as a bridge toward greater understanding and equity? Her investigative rigor, combined with deep empathy for humanity's most pressing challenges, shapes every story we publish here.
Comments (1)

Suggested Reading

Rethinking Medications: Truth, Power, and the Drugs You Take

Groundbreaking research has given us many remarkable new medicines, but America’s drug evaluation process, once the envy of the world, is being seriously compromised. Under pressure from drugmakers, the FDA has been lowering its approval standards and has let poorly effective or risky products enter...

Generation Priced Out: Who Gets to Live in the New Urban America

Generation Priced Out is a call to action on one of the most talked-about issues of our time: how skyrocketing rents and home values are pricing the working and middle classes out of urban America. Randy Shaw tells the powerful stories of tenants, politicians, homeowner groups, developers, and activ...

Drugs, Money, and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices

In the warped world of prescription drug pricing, generic drugs can cost more than branded ones, old drugs can be relaunched at astronomical prices, and low-cost options are shut out of the market. In Drugs, Money and Secret Handshakes, Robin Feldman shines a light into the dark corners of the pharm...

We use cookies to improve your experience on our website. By continuing to browse, you accept our Cookie Policy and Privacy Policy.